Interview with Darren Ji, CEO, PharmaLegacy
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
Address: Building 7, 388 Jialilue Rd.,Zhangjiang High-Tech Park, Shanghai,China
Tel: (86) 21-6100 2280
Web: http://www.pharmalegacy.com/Home.aspx?lang=en
PharmaLegacy Laboratories is a leading preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Bone Metabolism, Immune Diseases, Inflammation, Oncology, and Orthopaedics and Tissue Engineering. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services for early proof of concept of therapeutics and fulfillment of regulatory requirement.
Aspiring to collaborate with our global clients to accelerate their missions to develop new therapies, PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
The PharmaLegacy management team consists of world-renowned scholars, top service scientists and seasoned business leaders from the US and Shanghai. We have fully established animal pharmacology models of rodents, rabbits, dogs, sheep, goats and non-human primates which are used to serve our current clients of large multinational pharmaceutical and medical device companies, as well as small- to-medium-sized biotech companies.
Research
Could you give us some personal background and tell us why you choose to come to the CRO side after a successful career at a multinational? A lot of people…
CanSinoBIO was established to create high-quality, affordable vaccines for developing countries, addressing global health disparities. Having already developed an inhalable COVID-19 vaccine, the Chinese firm is now working on new…
Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the…
We last spoke with Xueming Qian, CEO and co-founder of the biotech Transcenta in 2019. Since then, the company has seen some important milestones: listing on the Hong Kong Stock…
General manager Guillaume Delmotte explores Ipsen’s strategic initiatives in China, highlighting the importance of innovation, addressing healthcare challenges, and fostering a sustainable, people-centric organization. Delmotte emphasizes the rapid pace of…
After a Big Pharma career in the US, Dr Yao-Chang Xu returned to China and in 2016 founded Abbisko, a biotech that began with a focus on small molecule oncology…
A roundup of some of the biggest pharma industry news from China, including Fosun’s bid for Henlius Biotech; the revision of the US’s Biosecure Act to provide more time for…
Writing exclusively for PharmaBoardroom, Song Ruilin of the China Pharmaceutical Innovation and Research Development Association (PhIRDA) outlines some of the key improvements and optimisations in the regulatory landscape for pharmaceutical…
Former director general of the Chinese Center for Disease Control and Prevention (CDC) and current chairman of the Chinese Foundation for Hepatitis Prevention and Control, Professor Yu Wang, weighs in…
After a glittering career in corporate America, in 2011 Jasmine Cui returned to China and in 2015 launched her own biotech, Innocare. The firm, which focuses on oncology and autoimmune…
Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been…
Jimmy Wei founded Chime Biologics over 12 years ago with the vision of establishing a global biologics company in China, focusing on biosimilar development and CDMO services. The company’s growth…
Boan Biotech CEO Jiang Hua outlines the Luye Pharma-acquired company’s approach, securing stable revenues through its biosimilars while pursuing novel platforms and innovative drug development. She provides insights into the…
See our Cookie Privacy Policy Here
